Kerala Ayurveda Ltd. (KERALAYUR) Share Price Rises 8.53% Today as Micro Cap Stock Gains
- August 18, 2026
- Posted by: Harsh Piplani
- Category: News
Kerala Ayurveda Ltd. traded at Rs 185.7, up 8.53% today, taking its market capitalisation to Rs 208.7 crore and placing the micro cap stock among notable BSE gainers.
Kerala Ayurveda Ltd. Share Price moved up to Rs 185.7 on 18 August 2026, a gain of 8.53% from the previous close of Rs 171.1, lifting the company’s market capitalisation to Rs 208.7 crore. In today’s Stock Market Today action, the move puts the healthcare name among the stocks rising today and marks it as a top gainer within the micro cap space.
The session data shows a clear same-day price rise rather than a longer-term milestone. The stock opened at Rs 171.1, touched an intraday high of Rs 186.8, slipped to a low of Rs 170, and was last seen near the upper end of that band at Rs 185.7. That pattern matters because it shows the share price gain held through the session instead of fading back toward the open.
The supplied data confirms the event but does not establish a company-specific catalyst behind today’s rally. What it does show is stronger price action on the BSE, where 44,479 shares changed hands, translating into turnover of Rs 0.83 crore. For investors tracking Kerala Ayurveda Ltd. Stock News, the immediate questions are straightforward: what exactly happened in the session, how convincing was the trading participation, how do the fundamentals compare with the Pharmaceuticals & Drugs benchmark, and what should be monitored next. Univest examines each of those points below using only the verified numbers available.
Kerala Ayurveda Ltd. (KERALAYUR) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 185.7 |
| Previous Close | Rs 171.1 |
| Today's Change | +Rs 14.6 (+8.53%) |
| Day Open | Rs 171.1 |
| Day High | Rs 186.8 |
| Day Low | Rs 170 |
| Current Volume (BSE) | 44,479 |
| BSE Traded Volume | 44,479 |
| Combined NSE + BSE Volume | 44,479 |
| Turnover | Rs 0.83 crore |
| Market Capitalisation | Rs 208.7 crore |
| Market Cap Category | Micro Cap |
Kerala Ayurveda Ltd. (KERALAYUR) traded at Rs 185.7. versus the previous close of Rs 171.1, a rise of 8.53%. The stock opened at Rs 171.1, reached Rs 186.8, touched Rs 170. Reported volume was 44,479.
Kerala Ayurveda Ltd. (KERALAYUR) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 208.7 crore |
| P/E Ratio | -9.1x |
| P/B Ratio | -11.02x |
| ROE | -183.03% |
| ROCE | -0.45% |
| EPS | Rs -20.41 |
| Dividend Yield | 0% |
Kerala Ayurveda Ltd. was valued at a P/E ratio of -9.1x, a P/B ratio of -11.02x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -183.03% and ROCE of -0.45%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs -20.41, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Kerala Ayurveda Ltd. Fundamental Analysis presents a mixed picture: today’s price action was strong, but the supplied valuation and profitability numbers remain weak. With a market capitalisation of Rs 208.7 crore, the company is clearly positioned at the smaller end of the listed healthcare universe, and its current ratios show losses rather than established earnings strength.
That profitability profile is clearly weak in the supplied dataset. Return on equity is -183.03%, while return on capital employed is -0.45%. Both figures indicate that the recent earnings base has not translated into positive returns for either shareholder equity or overall capital employed. EPS, another key authenticity metric in Kerala Ayurveda Ltd. Stock Analysis, is -20.41, confirming a loss per share on the reported basis used for this dataset.
Dividend yield stands at 0, meaning Kerala Ayurveda Ltd. Share Price is not currently being supported by a historical cash-yield component in this data snapshot. That matters because some smaller healthcare names attract investors through stable payouts; here, the focus shifts more toward business turnaround potential, sector positioning and trading momentum rather than current dividend income.
Even with those weak profitability numbers, today’s Kerala Ayurveda Ltd. Share Price Rise is still relevant because market action and company fundamentals do not always move in lockstep over a single session. Univest therefore views the current setup as one where trading interest has clearly improved today, while the underlying financial ratios still argue for close monitoring of earnings quality, profitability recovery and valuation context before drawing broader conclusions. That naturally leads into the sector and industry benchmark comparison.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | -9.1x |
| Benchmark Median P/E | 26.24x |
| Benchmark Average P/E | 39.98x |
| Benchmark P/E Range | 2.96x to 359.13x |
| Company P/B Ratio | -11.02x |
| Benchmark Median P/B | 1.82x |
| Company ROE | -183.03% |
| Benchmark Median ROE | 10.49% |
| Company ROCE | -0.45% |
| Benchmark Median ROCE | 12.97% |
| Company Market Capitalisation | Rs 208.7 crore |
| Benchmark Median Market Cap | Rs 142.37 crore |
Kerala Ayurveda Ltd. (KERALAYUR) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Kerala Ayurveda Ltd. (KERALAYUR) has a P/E ratio of -9.1x, which is below the benchmark median of 26.24x, a difference of -134.68%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Kerala Ayurveda Ltd. (KERALAYUR) has a ROE of -183.03%, which is below the benchmark median of 10.49%, a difference of -1,844.8%. Kerala Ayurveda Ltd. (KERALAYUR) has a ROCE of -0.45%, which is below the benchmark median of 12.97%, a difference of -103.47%.
Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.
Kerala Ayurveda Ltd. operates in Healthcare within the Pharmaceuticals & Drugs industry, and the benchmark data provides useful perspective. Its valuation and profitability metrics sit well below the industry medians and averages supplied for the same industry, even though its market capitalisation is above the benchmark median for the peer set.
The sector snapshot covers the same industry benchmark across 136 companies. Within that universe, Kerala Ayurveda Ltd. Share Price is tied to a company P/E of -9.1 versus an industry median P/E of 26.24 and an average of 39.98, based on 105 companies with P/E data. The benchmark range runs from 2.96 to 359.13. On that basis, Kerala Ayurveda’s negative P/E sits below both the median and average and outside the typical positive earnings valuation range carried by much of the group.
The P/B comparison tells a similar story. The company P/B is -11.02, while the industry median is 1.82 and the average is 2.49 across 135 companies. The supplied P/B range extends from -11.02 to 16.76, placing Kerala Ayurveda at the very bottom of that range. That does not by itself explain today’s move, but it does show that Kerala Ayurveda Ltd. Fundamental Analysis remains distinctly different from the industry centre.
Profitability gaps are equally visible. Company ROE of -183.03% compares with an industry median of 10.49% and average of 8.1%. Company ROCE of -0.45% compares with a median of 12.97% and average of 15.53%. In both cases, Kerala Ayurveda trails the benchmark. On size, however, the company’s market capitalisation of Rs 208.7 crore is above the industry median of Rs 142.37 crore, though still below the average of Rs 492.43 crore. The benchmark market-cap range spans from Rs 6.06 crore to Rs 2,985.15 crore. For Kerala Ayurveda Ltd. Share Price Today, the industry context shows a stock that is larger than the median company in its set, but far weaker on current profitability metrics.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,985.15 | 170.32 | 0.42 | -2.89 | -0.26 |
| Beta Drugs Ltd. | BETA | 2,827.67 | 65.02 | 10.29 | 18.65 | 22.17 |
| Hikal Ltd. | HIKAL | 2,686.72 | 0 | 2.2 | 15.22 | 16.15 |
| Ind-Swift Laboratories Ltd. | INDSWFTLAB | 2,645.37 | 47.53 | 1.82 | -0.78 | 8.31 |
| Fredun Pharmaceuticals Ltd. | FREDUN | 2,559.68 | 54.85 | 8.19 | 11.42 | 13.15 |
Kerala Ayurveda Ltd. (KERALAYUR) has a P/E ratio of -9.1x compared with the displayed peer median of 54.85x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -183.03% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at -0.45% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. Kerala Ayurveda Ltd. (KERALAYUR) has a market capitalisation of Rs 208.7 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Peer data shows Kerala Ayurveda Ltd. in a very different financial position from larger listed Pharmaceuticals & Drugs names supplied in the comparison set. Its market capitalisation, profitability and valuation profile all stand apart, which helps explain why investor attention may focus more on trading momentum than on established sector leadership.
Against the peer list, Kerala Ayurveda Ltd.’s market capitalisation of Rs 208.7 crore is substantially smaller than Dishman Carbogen Amcis Ltd. at Rs 2,985.15 crore, Beta Drugs Ltd. at Rs 2,827.67 crore, Hikal Ltd. at Rs 2,686.72 crore, Ind-Swift Laboratories Ltd. at Rs 2,645.37 crore and Fredun Pharmaceuticals Ltd. at Rs 2,559.68 crore. It is also below Solara Active Pharma Sciences Ltd. at Rs 2,465.73 crore, Sai Parenteral’s Ltd. at Rs 2,438.25 crore, Panacea Biotec Ltd. at Rs 2,429.2 crore, Venus Remedies Ltd. at Rs 2,388.41 crore and NGL Fine-Chem Ltd. at Rs 2,139.2 crore.
On valuation, Kerala Ayurveda Ltd.’s P/E of -9.1 sits below positive P/E peers such as Venus Remedies at 20.48, NGL Fine-Chem at 31.64, Ind-Swift Laboratories at 47.53, Fredun Pharmaceuticals at 54.85, Beta Drugs at 65.02, Dishman Carbogen Amcis at 170.32 and Sai Parenteral’s at 170.53. Some peers in the supplied set do not carry a P/E figure here, but where available, Kerala Ayurveda clearly screens as the outlier because of its negative earnings base.
The same is true on profitability. Kerala Ayurveda’s ROE of -183.03% is far below Beta Drugs at 18.65%, Hikal at 15.22%, Fredun at 11.42%, Venus Remedies at 9.85% and NGL Fine-Chem at 27.9%. Even peers with weak or low returns, such as Dishman Carbogen Amcis at -2.89%, Ind-Swift Laboratories at -0.78% and Panacea Biotec at 0, remain far ahead on this specific metric. ROCE of -0.45% also trails NGL Fine-Chem at 33.91%, Beta Drugs at 22.17%, Hikal at 16.15%, Solara at 15.34%, Fredun at 13.15%, Sai Parenteral’s at 12.97%, Ind-Swift at 8.31%, Venus Remedies at 7.89% and Panacea Biotec at 5.36%, while sitting slightly below Dishman Carbogen Amcis at -0.26%.
For Kerala Ayurveda Ltd. Share Price, the peer picture is clear: today’s move stands out on price performance, but the company’s current financial ratios remain materially weaker than most of the larger peer group in the same industry basket.
Why Investors Are Watching Kerala Ayurveda Ltd.
Kerala Ayurveda Ltd. Share Price is drawing attention because today’s gain was large enough to place the stock among notable Top Gainers Today in the micro cap segment. The move also held close to the session high, which is often why a stock begins trending in intraday Kerala Ayurveda Ltd. News Today and broader BSE News screens.
- Verified price action: the stock rose Rs 14.6, or 8.53%, from Rs 171.1 to Rs 185.7.
- Intraday position: it traded between Rs 170 and Rs 186.8 and held near the top of that range.
- Participation: BSE volume stood at 44,479 shares, with turnover of Rs 0.83 crore.
- Market-cap context: Kerala Ayurveda remains a micro cap with a market capitalisation of Rs 208.7 crore.
- Fundamental backdrop: P/E at -9.1, P/B at -11.02, ROE at -183.03%, ROCE at -0.45% and EPS at -20.41 show weak current profitability.
- Sector position: its profitability metrics remain below the Pharmaceuticals & Drugs benchmark medians and averages.
What should investors monitor next? Kerala Ayurveda Ltd. Share Price Update discussions are likely to focus on whether trading activity remains elevated after today’s move, whether the stock continues to hold near the upper end of its recent session range, and whether future Kerala Ayurveda Ltd. Earnings or company disclosures improve the weak profitability ratios currently visible in the data. Univest would also watch how the stock compares with peer valuations if business metrics change.
About Kerala Ayurveda Ltd.
Kerala Ayurveda Ltd. belongs to the Healthcare sector and is classified under the Pharmaceuticals & Drugs industry in the supplied market dataset. That places the company within a broad listed universe where 136 same-industry companies are used for benchmark comparison, ranging from micro-cap names to companies with market values approaching Rs 2,985.15 crore.
Although the supplied data does not include a business-segment breakdown, the market classification itself is still informative for Kerala Ayurveda Ltd. Company News readers. Pharmaceuticals & Drugs companies are typically assessed by investors through a combination of earnings profile, balance-sheet strength, return ratios and relative valuation. In Kerala Ayurveda Ltd.’s case, the market is currently assigning a micro cap valuation of Rs 208.7 crore while also reflecting negative EPS of -20.41, ROE of -183.03% and ROCE of -0.45% in the financial snapshot available here.
That means Kerala Ayurveda Ltd. Shareholding Pattern discussions cannot be expanded from this dataset, but sector placement still matters. The stock sits above the industry median market capitalisation of Rs 142.37 crore, though below the average of Rs 492.43 crore, which suggests it is not among the smallest names in its industry universe. At the same time, its valuation and return profile differs sharply from many listed healthcare peers. For investors following Kerala Ayurveda Ltd. Latest News, the company remains a niche listed Pharmaceuticals & Drugs stock where market movement and financial quality need to be read together rather than in isolation.
Track Kerala Ayurveda Ltd. Share Price on Univest
Use Kerala Ayurveda Ltd. (KERALAYUR) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.
Investors following Kerala Ayurveda Ltd. Share Price can use Univest to track live Share Price, day-wise Stock Performance, market capitalisation changes and key ratio trends in one place. Univest also helps users monitor valuation measures such as P/E Ratio and P/B Ratio, profitability metrics including ROE, ROCE and EPS, as well as 52 Week High and 52 Week Low data when available.
For traders and long-term market watchers alike, Univest makes it easier to compare Kerala Ayurveda Ltd. Share Price Today with peer stocks, review sector benchmarks, study recent Stock Updates and keep an eye on price-action-driven entries in Stocks in News lists. That is especially useful on sessions like today, when a micro cap name becomes a visible Market News story because of a sharp single-day gain.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Kerala Ayurveda Ltd. Share Price today?
Ans. Kerala Ayurveda Ltd. Share Price was Rs 185.7 at the time of this update on 18 August 2026. That placed the stock Rs 14.6 above its previous close of Rs 171.1, translating into a same-day gain of 8.53%.
Why is Kerala Ayurveda Ltd. rising today?
Ans. The supplied data confirms that Kerala Ayurveda Ltd. rose 8.53% in today’s session and qualified as a notable micro cap price rise. However, the verified dataset establishes the move itself and trading figures, not a company-specific reason behind it.
What were the day high and day low for Kerala Ayurveda Ltd. today?
Ans. Kerala Ayurveda Ltd. traded between a day low of Rs 170 and a day high of Rs 186.8. With the stock at Rs 185.7 during the event, it was trading very close to the upper end of its intraday range.
How much did Kerala Ayurveda Ltd. gain in rupee terms?
Ans. Kerala Ayurveda Ltd. gained Rs 14.6 over the previous close of Rs 171.1. That rupee increase translated into an 8.53% rise, making the stock one of the more visible micro cap gainers in today’s BSE trade.
What is the market capitalisation of Kerala Ayurveda Ltd.?
Ans. Kerala Ayurveda Ltd. had a market capitalisation of Rs 208.7 crore in the supplied data. That places the company in the micro cap category and above the industry median market capitalisation of Rs 142.37 crore.
How active was trading volume in Kerala Ayurveda Ltd. today?
Ans. The stock recorded BSE volume of 44,479 shares, and total volume in the supplied dataset was also 44,479 shares. Turnover stood at Rs 0.83 crore, giving useful context to today’s price rise and participation levels.
What do Kerala Ayurveda Ltd.'s valuation ratios show?
Ans. Kerala Ayurveda Ltd. was trading with a P/E ratio of -9.1 and a P/B ratio of -11.02. Both figures differ sharply from the Pharmaceuticals & Drugs benchmark, where the median P/E was 26.24 and median P/B was 1.82.
How profitable is Kerala Ayurveda Ltd. based on the supplied data?
Ans. The supplied profitability snapshot is weak, with ROE at -183.03%, ROCE at -0.45% and EPS at -20.41. These numbers indicate that current reported earnings and returns remain under pressure despite today’s strong share price gain.
How does Kerala Ayurveda Ltd. compare with industry peers?
Ans. Kerala Ayurveda Ltd. is much smaller than peers such as Dishman Carbogen Amcis, Beta Drugs and Hikal by market capitalisation. Its negative P/E, negative ROE and negative ROCE also compare unfavourably with most supplied Pharmaceuticals & Drugs peers.
What should investors monitor after today’s move in Kerala Ayurveda Ltd.?
Ans. Investors may track whether Kerala Ayurveda Ltd. holds near today’s upper trading range, whether volume remains active after the 8.53% rise, and whether future earnings data improves the current profitability metrics, including EPS, ROE and ROCE.
